SUMMARY
INTRODUCTION
Nowadays, reported results regarding the usage of hormone treatment (HT) in menopause are contradictory. According to the results of a randomized study, it was stated that HT isn't useful and may even be harmful in preventing the cardiovascular diseases during post menopause and that breast cancer increased in women (1) . Due to these contradictions, HT is recommended to be used in minimal acting doses and for short term in the cases with dominant vasomotor symptoms. Increase of low density lipoprotein (LDL), cholesterol and triglyceride, hyperinsulinemia and hyperandrogenemia are the risk factors for coronary heart diseases (4) . Negative effects of the medicines on lipid and carbohydrate metabolism and endogen androgens should be taken into consideration when choosing HT. Positive changes determined in serum lipids during treatment with high dose HT were also determined during treatment with low dose HT (5) .
Besides, continuous combined estrogen-progesterone preparations increase the thyroid binding globulin (TBG) level but don't affect the thyroid stimulating hormone (TSH) and free thyroxin (fT4) level (7) .
Norethysterone acetate (NETA) is a C-19 derivative and a strong progestational agent causing significant atrophy in endometrium compared to other progesterone compounds (2) . Nowadays, low dose HT-1 mg E2/ 0.5 mg NETA combination-is preferred because it both decreases vasomotor symptoms and vaginal bleeding incidence is very low (2, 3) .
Furthermore, it has been reported that HT in postmenopausal period is more appropriate because of the positive effects of estrogen and NETA combination on insulin sensitivity (6) . Low dose-1 mg E2/ 0.5 mg NETA-combination significantly decreases the fibrinogen level compared to the control (8) and doesn't change the serum androgen levels (9) .
Drospirenone with antiandrogenic and antimineralocorticoid activity is a new gestagen closest to natural progesterone and doesn't affect the beneficial effects of estrogen negatively (10) . Drospirenone positively effects lipid metabolism by decreasing LDL cholesterol (10) . It doesn't increase the risk in terms of cardiovascular diseases because it doesn't change the fasting blood glucose, insulin, fibrinogen and C-reactive protein levels in short-term treatment (11) .
There are publications in literature comparing the effects of NETA and drospirenone on a single system separately. In this study, it was aimed to compare the effects of short term usage of low dose HT preparations containing NETA and drospirenone on both serum androgens, thyroid hormones and, lipid and carbohydrate metabolisms.
MATERIAL AND METHODS
50 cases who has gone through menopause naturally and been in menopause for at least 1 year and attended to our hospital's menopause policlinic with vasomotor symptoms between the dates 01.03.05 -01.07.06 were enrolled in our study, 41 cases completed the study. 
RESULTS
The study was started with 50 cases and 41 of them completed the study. 4 cases from Group I and 5 cases from Group II were withdrawn from the study because No statistical difference was determined among 2 groups in terms of age, exercise habit and BMI (Table I) . Ages of the subjects were between 46 and 52 (mean, group I: 47.86 ± 3.21, group II: 46.4 ± 3.42) and menopause ages were between 1 and 3 years. Smoking habit was significantly higher in group II (p=0.01).
There wasn't any difference in endometrial thickness measurements between two groups before and after the treatment (Table I) . No difference in endometrial thickness was determined within the group in both groups after the 3 months treatment. BMI didn't differ within the group and among the groups at the end of the treatment (Table I) .
There was no difference in lipid parameters between the groups before the treatment (Table II) ; at the end of the 3 months of treatment, triglyceride (p=0.05) and VLDL cholesterol (p=0.008) were higher in group II.
At the end of the treatment, total cholesterol in group I (p=0.03) and LDL cholesterol in group II (p=0.02) decreased significantly within the groups; triglyceride increased in group II (p=0.04) (Table II) The effects of low dose hormone therapy on serum lipid profile, glisemic control, thyroid hormones and androgen levels in postmenopausal women no difference between the groups (Table IV) .
APTT didn't change with the treatment whereas fibrinogen decreased significantly within the group I (p=0.01) (Table IV) . When percentage change differences were calculated before and after the treatment, increases in triglyceride and APTT in group II were significant compared to the decrease in group I (p=0.05, p=0.04 respectively) (Table V) .
Vaginal spotting occurred in 2 cases in group I (9.5 %) and in 3 cases in group II (15 %) . No adverse effects were seen in the cases except for mastalgia development in 2 cases in group I (9.5 %). Besides, none of these women stopped taking the medicine at the end of three months because of the adverse effects. 
DISCUSSION
In this prospective study, effects of low dose HT regimen containing NETA and drospirenone on carbohydrate and lipid metabolisms and on thyroid and androgen hormone levels were compared. While NETA combination significantly decreased fasting insulin, HOMA, total cholesterol, total testosterone and fibrinogen levels, drospirenone combination significantly decreased LDL cholesterol and total testosterone levels. Drospirenone also significantly increased triglycerides. When two medicines were compared, triglyceride and APTT increasing of drospirenone was found more significant than that of NETA.
It has been reported that NETA's effect on lipid metabolism was decrease in total and LDL cholesterol; slight decrease in HDL cholesterol and none on triglyceride (13, 14) . Consistent with the literature, significant decrease in total cholesterol and slight decrease in HDL, LDL, VLDL and triglyceride with NETA were also determined in this study. It has been suggested that drospirenone decreases the total cholesterol, LDL, VLDL (15, 16) ; increases (16) or doesn't affect (15, 17) HDL due to its antiandrogenic effects. In this study it was determined that drospirenone decreased the total cholesterol slightly and LDL significantly, the results were consistent with the literature. There are publications stating that drospirenone doesn't affect (15) , slightly increases (16) and increases the triglyceride at high doses (18) (19) (20) . In this research significant increase in triglyceride level was determined in drospirenone group. When two medicines were compared after the treatment, triglyceride increase in drospirenone group was found to be more significant than the decrease in NETA group.
Effects of HT containing NETA on FBG and insulin sensitivity are controversial in the literature; there are publications stating that it has no effect or causes deterioration (21, 22) . Dansuk et al have reported that 2 mg E2 + 1 mg NETA changes the insulin sensitivity in postmenopausal women after a 3 months treatment (6) .
In this study, fasting blood glucose decreased slightly in NETA group and decreases in insulin and HOMA value were found to be statistically significant. It has been suggested that insulin increases the endothelial cell growth and regulates the LDL receptor activity, so decrease in fasting insulin level is a factor protecting from cardiovascular diseases (23) . While it has been notified that drospirenone's effect is increase in blood glucose and glucose tolerance (18, 19) , there are also opinions that it is ineffective on carbohydrate metabolism (11, 23) . Hyperandrogenism is one of the risk factors for cardiovascular diseases (4) . There are publications stating NETA is ineffective on androgens and also that it decreases the androgens (9, 24) . When androgens were monitored, DHEAS decreased in two groups slightly, total testosterone decreased in both groups significantly and no significant difference was determined between the groups.
In menopause period, fibrinogen increases with age and clearly decreases in HT areas (25) . Fibrinogen is one of the independent risk factors for myocardium infarction and paralysis (25) . In the study, fibrinogen decreased in both groups and this decrease was found statistically significant in NETA group. In literature it has been reported that NETA decreases (8) or doesn't affect (26) whereas drospirenone doesn't affect (11, 16) or increases (27) the fibrinogen. Kluft et al determined that
APTT decreased with drospirenone and stated that changes in haemostatic parameters are related to the estrogen dose rather than the gestagen in combined preparations (27) .
HT increases TBG, total T3, total T4 levels whereas it doesn't affect TSH, free T3 and free T4 levels (28) .
Therefore it is recommended to monitor TSH, free T3
and free T4 levels in order to determine the thyroid axis in women having HT (28) . In this study it was determined that NETA and drospirenone don't affect TSH, free T3 and free T4 levels. The first result different from the literature is the triglyceride increase in drospirenone group. Smoking ratio was determined to be significantly high in drospirenone group after the randomization; this high smoking ratio may also have caused the triglyceride increase. Because nicotine causes lipolysis with stimulation of sympathetic nervous system and decrease of catecholamine and as a result total cholesterol and triglyceride increase (29) . Besides, smoking changes the positive effects of estrogen on lipid profile by affecting the bioavailability of estrogen taken orally (18) .
Second difference is that drospirenone didn't cause statistically significant decrease in androgens though it has an antiandrogenic effect. Small sample size of work groups may have caused this.
Continuous combined low dose HT regimen is a good choice for the women in menopause who don't want the monthly bleedings caused by cyclic treatment. In the first months of treatment with this preparations, vaginal bleedings may be seen more frequently but they have the tendency to decrease in time (30, 31) . These bleedings seen in the first 3 months may reflect endometrial compatibility (30) . Vaginal spotting was seen in 9.5 % cases in NETA group and 15 % cases in drospirenone group but this difference wasn't found significant. Endometrial thickness demonstrated a slight increase without significance in both groups.
Limitations of our study were small sampling size, short treatment duration and absence of a control group.
Reasons for these are providing car for a limited numbers of case groups and that the subjects didn't lean towards medicine usage in menopause. Besides, patient population of low socio-economical level who immigrated from the countryside was big in our hospital so we had to limit the study period in 3 months due to both the difficulty of case follow-up and orientation to treatment, and the tendency to quit the long term treatment, medicine usage in particular.
Consequently, there are positive effects of NETA on haemostatic parameters and androgens apart from its positive effects on carbohydrate and lipid metabolism.
Drospirenone affects the lipid metabolism and androgens positively except the triglyceride increase whereas it doesn't affect the carbohydrate metabolism.
Low dose HT containing NETA would be a more appropriate choice especially for the cases with insulin resistance and diabetes risk in order to decrease the vasomotor symptoms. However studies with more subjects and long follow-up periods are required in order to get to a definite conclusion.
